55 completed, 15 terminated, 12 unknown, 9 withdrawn. 103 Phase 2, 21 Phase 1, 9 Phase 3.
Follow Uveitis: new trials by email Literature Review of Uveitis trials Research Report on Uveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019) Tulisokibart, Placebo, Background prednisone therapy - Noninfectious Intermediate, Posterior, or Panuveitis | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 87 | 2026-11-04 | 2026-11-09 |
| Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis | Phase 2 | Not yet recruiting | University of California, San Francisco | 117 | 2026-11-01 | 2026-08-11 |
| Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym. Repository Corticotropin Injection (ACTH), Study-matched inactive placebo injection, also called control injection - Behçet's Syndrome, Behçet's Syndrome (BS) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 60 | 2026-09-01 | 2026-09-22 |
| A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis. GenSci048, Placebo - Uveitis | Phase 2 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 74 | 2026-06-29 | 2026-07-24 |
| Ivarmacitinib for Refractory Behcet's Syndrome Ivarmacitinib - Behcet's Syndrome | Phase 2 | Withdrawn | Liu Tian | 2026-06-01 | 2026-07-10 | |
| A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU FXS5626 tablet, Placebo - Active Non-anterior, Non-infectious Uveitis | Phase 2 | Recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 40 | 2026-01-29 | 2026-10-15 |
| A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants REGN7041 - Active Noninfectious Uveitis Affecting the Posterior Segment | Phase 1 / Phase 2 | Terminated | Regeneron Pharmaceuticals | 1 | 2025-12-17 | 2026-08-17 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Dusquetide for the Treatment of Behcet's Disease Dusquetide - Behçet Disease | Phase 2 | Completed | Soligenix | 8 | 2024-11-18 | 2026-08-26 |
| Baricitinib in the Treatment of Intestinal Behçet's Syndrome Baricitinib, Adalimumab - Behcet Syndrome, Intestinal Type | Phase 2 | Recruiting | Peking Union Medical College Hospital | 56 | 2024-11-08 | 2026-09-21 |
| Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome Ustekinumab 90 mg - Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome | Phase 2 | Completed | Liu Tian | 8 | 2024-03-24 | 2026-05-13 |
| Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Filgotinib - Behcet's Disease, Idiopathic Inflammatory Myopathies | Phase 2 | Recruiting | UMC Utrecht | 60 | 2024-03-12 | 2026-05-12 |
| Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis Oftac: 0.05% tacrolimus ophthalmic emulsion - Non-Infectious Anterior Uveitis | Phase 1 / Phase 2 | Completed | BioNanoSim Ltd. | 18 | 2024-03-07 | 2026-10-13 |
| Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers Topical Pentoxifylline Gel (Vehicle +PTX), Topical Placebo Gel (Vehicle) - Behcet Syndrome, Behcet Disease | Phase 2 | Unknown | Silk Road Therapies, Inc. | 60 | 2024-02-01 | 2023-08-03 |
| Upadacitinib for Refractory Behcet's Syndrome Upadacitinib 15 MG - Behcet Syndrome | Phase 2 | Completed | Liu Tian | 27 | 2024-01-25 | 2025-12-02 |
| A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Prednisolone acetate - Anterior Uveitis | Phase 2 | Completed | VivaVision Biotech, Inc | 89 | 2023-11-27 | 2025-01-27 |
| POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU ESK-001 - Uveitis Posterior Non-Infectious, Uveitis, Intermediate | Phase 2 | Terminated | Alumis Inc | 36 | 2023-06-14 | 2024-08-28 |
| Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome tocilizumab, tofacitinib, cyclophosphamide - Aneurysm, Behcet Syndrome, Vascular Type | Phase 2 | Recruiting | Peking Union Medical College Hospital | 81 | 2023-06-01 | 2024-08-19 |
| Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema OCS-01 - Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative | Phase 2 | Active not recruiting | Quan Dong Nguyen | 28 | 2023-05-26 | 2026-11-02 |
| A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis Brepocitinib - Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis | Phase 2 | Completed | Priovant Therapeutics, Inc. | 26 | 2022-11-14 | 2025-07-25 |
Showing 20 of 103. Sign in to see all of them.
Behcet Syndrome (28) · Uveitis, Posterior (16) · Uveitis, Intermediate (15) · Macular Edema (13) · Uveitis, Anterior (13) · Panuveitis (10) · Inflammation (5) · Arthritis, Juvenile (3) · Retinal Diseases (3) · Retinal Vasculitis (3) · Birdshot Chorioretinopathy (2) · Choroidal Effusions (2) · Diabetes Mellitus, Insulin-Dependent, 10 (2) · Immunoglobulin G4-Related Disease (2)
Uveal Diseases (103) · Eye Diseases (102) · Panuveitis (49) · Skin and Connective Tissue Diseases (32) · Cardiovascular Diseases (30) · Vascular Diseases (30) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (29) · Genetic Diseases, Inborn (29) · Skin Diseases (29) · Skin Diseases, Vascular (29) · Vasculitis (29) · Hereditary Autoinflammatory Diseases (28) · Mouth Diseases (28) · Skin Diseases, Genetic (28)
Adalimumab (6) · Daclizumab (5) · tocilizumab (5) · Methotrexate (4) · Dexamethasone (3) · Prednisone (3) · Ustekinumab (3) · prednisolone acetate (3) · Abatacept (2) · Adrenal Cortex Hormones (2) · Adrenocorticotropic Hormone (2) · Cyclophosphamide (2) · Interleukin 1 Receptor Antagonist Protein (2) · Interleukin-2 (2) · Intravitreal Injections (2)
National Eye Institute (NEI) (13) · Assistance Publique - Hôpitaux de Paris (6) · Novartis Pharmaceuticals (4) · Allergan (3) · Liu Tian (3) · Oregon Health and Science University (3) · Peking Union Medical College Hospital (3) · ACELYRIN Inc. (2) · Benha University (2) · Clearside Biomedical, Inc. (2) · Fakultas Kedokteran Universitas Indonesia (2) · Merck Sharp & Dohme LLC (2) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (2) · Peking University People's Hospital (2) · Quan Dong Nguyen (2)
United States (50) · China (18) · France (10) · Germany (6) · Turkey (Türkiye) (5) · United Kingdom (5) · Czechia (3) · Israel (3) · Spain (3) · Austria (2) · Egypt (2) · India (2) · Indonesia (2) · Iran (2) · Italy (2)
Hatice N Sen, M.D. (3) · Quan D Nguyen, MD, MSc (3) · Bahar Sadeghi, MD (2) · Hatice Nida Sen, MD, MHSc (2) · James T Rosenbaum, MD (2) · Thomas Ciulla, MD (2) · Wenjie Zheng, M.D. (2) · Ahmed A Abdelshafy, MD (1) · Ahmed Abdelshafy, MD (1) · Ahmet Gul, MD (1) · Albert T Vitale, MD (1)
PMID 37172782, PMID 15079763, PMID 17353400, PMID 19268890, PMID 19597921, PMID 19664754, PMID 1970380, PMID 19717547, PMID 20212194, PMID 20212197, PMID 20704622, PMID 20926833, PMID 21220619, PMID 21913066, PMID 23411886, PMID 23761087, PMID 25638011, PMID 25875256, PMID 27980877, PMID 28335798, PMID 28528519, PMID 29275333, PMID 29471416, PMID 30009894, PMID 30472651, PMID 32377822, PMID 32955967, PMID 33042579, PMID 34864108, PMID 36585127, PMID 37316690, PMID 38652891, PMID 38782788, PMID 39915014, PMID 41018498, PMID 41400947, PMID 41643758, PMID 41748391
2025 (2), 2014 (1), 2016 (1), 2018 (1), R44EY014772 (1), UG1EY036344 (1)